Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 convalescent plasma (UNC Chapel Hill)
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
COVID-19 convalescent plasma (CCP) is a biologic therapy derived from the blood of individuals who have recovered from a SARS-CoV-2 infection. This specific investigational product was utilized in the CoronaVirus Inactivating Plasma (CoVIP) study, a Phase 2 clinical trial (NCT04524507) led by the University of North Carolina at Chapel Hill. The plasma contains high titers of neutralizing antibodies that specifically target the SARS-CoV-2 virus, binding to viral surface proteins to prevent host cell entry and facilitate viral clearance. The UNC study was designed to compare the efficacy and safety of standard-titer versus high-titer (neutralizing antibody titers >1:640) plasma in hospitalized patients with early-stage COVID-19 symptoms.
- Other names
- COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCPCoronaVirus Inactivating PlasmaAnti-SARS-CoV-2 neutralizing antibody plasmaAnti-SARS-CoV2 neutralizing antibody plasmaAnti-SARS-CoV 2 neutralizing antibody plasma
02
Targets
ORF3a (SARS-CoV-2 ORF3a protein)M protein (SARS-CoV-2 membrane protein)N (Nucleocapsid protein)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on COVID-19 convalescent plasma (UNC Chapel Hill).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 convalescent plasma (UNC Chapel Hill).